The Medicines and Healthcare products Regulatory Agency said it has approved Zurzuvae to treat moderate or severe postnatal depression in adults following childbirth. Zuranolone is the first oral treatment for postnatal depression approved in the UK, the agency said in a statement. The approval was granted to Biogen (BIIB).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen, Stoke Therapeutics present data from studies of zorevunersen
- Eisai and Biogen launch Leqembi in Austria, Germany
- Biogen’s Innovative Study on Litifilimab Delivery: Market Implications and Study Insights
- Biogen’s Phase 3 Study on Felzartamab: A Potential Game-Changer for IgA Nephropathy
- Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment?